Specific oncogene may serve as marker for lung squamous cell carcinoma

Share this content:
Researchers have identified an oncogene that is linked specifically to lung squamous cell carcinoma, according to a study published in PLoS Medicine (2010 Jul 27;7(7):e1000315).

For the study, William Lockwood and colleagues from the BC Cancer Agency's Research Centre in Vancouver, Canada used a comparative genetic hybridization technique to show that the focal amplification of chromosome region 8p12 played a role in the development of lung squamous cell carcinoma but not in the development of lung adenocarcinoma, where DNA loss in this chromosomal region is the most common alteration.

Researchers identified the oncogene, called BRF2, and reported that it was frequently activated in pre-invasive stages of lung squamous cell carcinoma—carcinoma in situ and dysplasia.

“This is the first study, to our knowledge, to show that the focal amplification of a gene in chromosome 8p12 plays a key role in squamous cell lineage specificity of the disease. Our data suggest that genetic activation of BRF2 represents a unique mechanism of lung squamous cell carcinoma tumorgenesis,” the authors concluded. “It [BRF2] can serve as a marker of lung squamous cell carcinoma and may provide a novel target for therapy.”

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs